Fast Food Chain Wants To Personalize Munchie Cravings

Maria Loreto

-

March 28, 2019

Capitalizing on our need for our desires to meet immediately, this fast food chain wants to personalize munchie cravings. McDonald’s wants to revolutionize drive-thrus by offering their patrons a menu that’s personalized and that changes depending on factors like the weather, current restaurant traffic, and trending menu items.

Techcrunch reports that McDonald’s recently acquired Dynamic Yield, an investment that rumoredly cost them over $300 million, making it the company’s largest acquisition in over 20 years. Dynamic Yield is a company known for its partnerships with e-commerce and travel websites in order to develop an Amazon-like personalized experience for users.

Dynamic Yield’s technology will be used to develop a McDonald’s drive-thru menu that’s personalized, capable of recommending orders depending on each user’s interest, the weather, and more. The feature was tested on several locations throughout 2018 and is planned to roll out within the US in 2019. International markets will presumably adopt these features soon after.

If successful, McDonald’s will incorporate this technology into their self-serve kiosks and mobile app software, making it even harder for you to resist a late McDonald’s craving.

Via Dynamic Yield:

Dynamic Yield will play a critical role in McDonald’s digital transformation, allowing it to become even more focused on the customer by deploying our technology in outdoor digital Drive-Thru menu displays, as well as other digital customer experience touchpoints, such as self-order kiosks and the McDonald’s Global Mobile App.”

The company has a history of being cutting edge. McDonald’s was the first central international fast-food restaurant. And it had the first drive-thru window. The restaurant chain has experimented with ways to speed up service and cut down on costs and order-taking errors. McDonald’s was among the few fast-food chains that experimented with order-taking kiosks, putting them in place in 2015.

So, fast food chain wants to personalize munchie cravings? How can you say no to a Big Mac if your app knows your tastes so well?

The White House Lying About Marijuana And Fentanyl?

Mike Adams

-

March 28, 2019

0

The White House Lying About Marijuana And Fentanyl?

For the past few years, one of the greatest new-level propaganda schemes to come spewing from the mouths of local anti-marijuana squads is that fentanyl is being found in black market pot supplies. And while these claims have been mostly discounted, that hasn’t stopped leading White House officials from perpetuating the scam. It was just last week that one of President Trump’s leading experts on the opioid crisis warned that people who use marijuana should be afraid. So why is the White House lying about marijuana and fentanyl?

“People are unwittingly ingesting it,” said Kellyanne Conway, who serves as the administration’s czar on the opioid epidemic. “It’s laced into heroin, marijuana, meth, cocaine, and it’s also just being distributed by itself.”

It is true that fentanyl is being used as an additive to black market dope supplies. There is evidence of it turning up in drugs from heroin to cocaine and even methamphetamine. This is happening, or so it has been said, because fentanyl, a substance that is up to 50 times more potent than heroin, is a cheap way to cut these drugs. Yet, considering the bizarre drug mixtures found in the United States over the past year, chances are people are seeking out fentanyl-laced drugs to achieve a unique, speedball type of buzz.

But drug experts argue that no weed is being sold like this in the underground.

“It’s crazy that this story is coming out from our leaders,” Dan Ciccarone, an epidemiologist at University of California, San Francisco, said in an interview with BuzzFeed News. “It shows that concerns about fentanyl have reached the level of moral panic. Fear outweighs rational evidence. There is scant evidence for cannabis laced with fentanyl.”

If the White House is pushing the murderous marijuana narrative to scare the living bejeezus out of the American population, it’s a solid plan. The opioid crisis is a lean, mean killing machine, responsible for dumping somewhere between 45,000 and 70,000 bodies every year. Some of the latest statistics show that fentanyl is responsible for a significant chunk of the death toll. And it’s a problem that is growing and spiraling more out of control with every passing year.

But even the U.S. Drug Enforcement Administration (DEA), a federal law enforcement agency that would love nothing more than to Make Marijuana Dangerous Again admits that fentanyl-laced marijuana is not something it has seen. Earlier this month, the DEA ‘s senior chemist, Jill Head, said a deadly drug mixture of this kind would contribute to a more cataclysmic death count than what the nation is presently witnessing. Marijuana is used by 22 million people across the United States.

So why is the White House lumping weed in with it fentanyl spiel? Well, it turns out that it is just pulling misinformation that was reported by the National Institutes on Drug Abuse (NIDA).

Last year, NIDA director Nora Volkow said: “Fentanyl is being used to lace a wide variety of drugs, including marijuana.” However, this claim was based solely on “anecdotal reports” from local police departments—none of which have been substantiated in any way. In fact, many of these reports were eventually determined to be false. The lesson here is we can’t trust police to be drug experts.

“There’s this mistaken belief that law enforcement are experts on the drugs they are seizing,” Northeastern University drug policy expert Leo Beletsky told BuzzFeed News. “That’s just not the case, and that’s part of the problem.”

How Medical Marijuana Can Help With ADD And ADHD Focus

Brea Mosley

-

March 28, 2019

0

How Medical Marijuana Can Help With ADD And ADHD Focus

From hyperactivity to impulses and inattentiveness, ADD and ADHD are most common in children but can persist in adult years.

Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder (ADD/ADHD) is a chronic condition that affects over three million people per year.

From hyperactivity to impulses and inattentiveness, ADD and ADHD are most common in children but can persist in adult years. The chronic conditions is not curable, although treatment is available. Unfortunately, for some people, current treatment hasn’t been effective.

So what’s the next best contender? According to research, cannabis.

A 2013 study published in the Journal of Substance Use & Misuse found that people were self-medicating, in order to deal with and manage hyperactivity and impulsive—two major components of ADD/ADHD.

The study surveyed about 280 cannabis users and the main finding was that a higher proportion of users reported experiencing symptoms of ADD/ADHD when they were not self-medicating. This finding led researchers to push for more resources to study the link between the endocannabinoid symptom and cannabinoid.

Following the findings of the 2013 study, researchers in Germany sought to closely examine the relationship between cannabis and ADD in 30 patients. In the 2015 study, the researchers examined traditional treatment resistant patients from 2012 to 2014.

There were 28 male patients (as ADD/ADHD is more common in male) and two female patients, between the ages of 21-51 with the average age being around 30. In all 30 cases, patients reported improvements in a variety of ADD/ADHD symptoms including concentration and impulsivity. In other cases, patients saw an improvement in sleep. All patients used some form of cannabis flower and in eight patients, they used dronabinol, a THC drug used to treat nausea and vomiting.

Although the case study was small, researchers confidently concluded cannabis is “an effective and well-tolerated” treatment option – especially for patients where traditional pharmaceuticals fall short.

In reality, it should be no surprise that cannabis is a strong ally for people with ADD and ADHD. A study from almost 10 years ago examined the relationship between those with ADD/ADHD and dopamine levels.

People with the chronic condition experience lower levels of dopamine, the neurotransmitter responsible for mood and motivation. However, THC is known to increase dopamine quantities as well as the transmission of dopamine. Do you see the connection?

The most common ADD/ADHD treatments like Ritalin and Adderal may help sufferers concentrate or improve cognitive functions, but they have been noted to cause unappetizing side effects like nausea or vomiting. You know what’s good for that?

Cannabis.

Tom Brokaw Comes Out As Medical Marijuana User And Advocate

Brendan Bures

-

March 28, 2019

0

Tom Brokaw Comes Out As Medical Marijuana User And Advocate

Add Tom Brokaw to the growing number of public celebrities embracing medical marijuana. Long an American symbol of stalwart and at times fussy newsmen, Brokaw is in remission from multiple myeloma (a cancer that grows in bone marrow). However, the pain sustained in his bones from the cancer has turned Brokaw to medical marijuana.

“I’m now on medical marijuana for my back, for the first time,” Brokaw told SurvivorNet, a cancer information site. “I’ve not done that before.”

Brokaw admits that he’s no less ambitious a journalist and currently working on a book about Richard Nixon. “Politics keep me distracted from cancer,” he says. But when he’s not working on that, trying to acquire medical marijuana in Florida, where he resides, is “complicated” and almost a full-time job in itself.

In coming out as a marijuana advocate, Brokaw engenders himself to a growing number of cancer patients using medical marijuana in treatment. According to SurvivorNet’s CEO Steve Alperin, more people are trying to learn more about medical marijuana and having someone like Brokaw open up about his experience will “help people understand there are alternative approaches to pain management.”

That said, Brokaw says he’s “keenly aware” how fortunate his cancer battle has been. When he was diagnosed with multiple myeloma back in August 2013, he was immediately medevacked to the Mayo Clinic with a room already available for him. He went through years of treatment—including chemotherapy and spinal operations—but all that cost tons of money.

“An extraordinary amount of progress has been made with drugs and treatment. We haven’t gotten the cost thing worked out yet,” he told SurvivorNetOpens a New Window.. “At one point, I counted up the price and it was something like $10,000 a day, you know, that I was spending on drugs. I have the blessing of having a great program through first RCA, then GE, and now Comcast. So the checks that I write for pharmacy are very, very small. And it makes — every time I do that, it makes me aware of the people who are not in the same position that I am, and how I think about them.”

CVS Will Now Sell CBD Oil In 8 States

Maria Loreto

-

March 28, 2019

0

After much mystery, CVS will now sell CBD Oil in 8 states. They confirmed a partnership with Curaleaf, and will begin to sell CBD Oil in 800 of their locations. This number amounts to 10 percent of CVS shops, a huge step for cannabis since the drugstore is the largest one in America.

Cannabidiol has gained traction and recognition over the last couple of years, managing to weedle itself into all sorts of industries, primarily beauty and health. In terms of reach, CVS’s involvement is one of the most significant investments for the growing CBD industry.

CVS’s stores will market CBD oil as “relief source.” Products will be located in eight states, including California, Colorado and Nevada, which are some of the most cannabis friendly U.S. locations.

“We are carrying hemp-derived CBD products in select states to help meet consumer demand for alternative care options,” said CVS’s Health Spokesperson Mike DeAngelis.

Yahoo Finance reports that CVS’ partnership with Ceraleaf has resulted in a 17 percent increase in the cannabis company’s shares.

Although CBD is still heavily monitored within foods and beverages by the FDA, this acceptance by the health industry is a symptom of a much larger and welcoming phenomenon, putting cannabis investors in an interesting and unpredictable situation. No one can really say when these restrictions will loosen up, but if businesses take a chance and federal laws work in their favor they could see a incredible returns.

CVS has an innovative history. The first Consumer Value Store selling health and beauty products is founded in Lowell, Massachusetts in 1963. A year later, the name is changed to CVS. In 1972, CVS nearly doubles in size with the acquisition of 84 Clinton Drug and Discount stores. In 2015, CVS Health acquired Target’s 1,672 pharmacies across 47 states and will operate them through a store-within-a-store format, branded as CVS/pharmacy.

Pennsylvania Senators Unveil Bill To Foster An Adult-Use Cannabis Program

Green Market Report

-

March 28, 2019

0

Pennsylvania Senators Unveil Bill To Foster An Adult-Use Cannabis Program

Pennsylvania Senator Daylin Leach and Senator Sharif Street recently unveiled their plan to introduce legislation, Senate Bill 350 (“SB 350”), that—if passed—would legalize adult-use cannabis and create a corresponding regulatory program. SB 350 would permit adults over the age of 21 to purchase and consume adult-use cannabis, and, to grow up to six plants per household.

The state regulatory authority will license cannabis businesses, including cultivation facilities, processors, dispensaries, public lounges and delivery services. There is no limit as to how many licenses the regulatory authority may issue. Additionally, licensees currently active under the state’s medical cannabis program will automatically be issued licenses to enter into the adult-use cannabis space.

Cultivation licenses will be separated into two categories: macro-growers and micro-growers. Macro-growers will be traditional cultivation facilities, reserved for larger growing operations. In order to receive a cultivation license, the applicant will need to meet certain regulatory and financial requirements.

Micro-growers licenses, on the other hand, are designed to provide entry into the adult-use cannabis sphere; specifically, these are intended to encourage growth for businesses in areas that have been directly impacted by cannabis prohibition. Micro-growers can only grow and only sell their product to processors and dispensaries.

SB 350 also contemplates a tax on adult-use cannabis transactions. However, the bill does not include the rate that the tax will be imposed. Instead, the bill provides a standard for which the tax rate shall be determined. Specifically, the rate must ensure tax generation sufficient to undermine the illegal market, to invest in the communities that have been harmed by prohibition, and to satisfy the need to pay for industry regulation.

The majority of tax money generated from cannabis sales under SB 350 will go to Pennsylvania public schools. School districts will, however, have the opportunity to decide whether to use these taxes as an investment into their schools, or, rather, to lower local property taxes.

If passed, SB 350 will automatically expunge all criminal convictions related to possession of cannabis, cannabis paraphernalia, and possession with the intent to deliver less than an ounce of cannabis. Any eligible pending cannabis charges will be dismissed. Those who are currently serving sentences for possession or intent to deliver less than an ounce of cannabis will be commutated, and eligible terms of parole or probation related to cannabis offenses will be ended.

SB 350 proposes some features that are unique relative to other state adult-use cannabis programs. Specifically, it would do away with “seed-to-sale tracking,” one method similar programs have used to track regulated cannabis. Additionally, it proposes environmental standards (for example, dispensaries selling vape pens must offer recycling programs), social lounges, and home delivery.

Additionally, SB 350 proposes public education initiatives about cannabis. It proposes a statewide cannabis business institute, which will provide, at no cost to the public, education as to how to start and run a small business, how to grow and process cannabis, and how to be compliant with state and federal law. Those who complete this course will be eligible to apply for state grants and interest-free loans to start a cannabis business. The program would further allow colleges and universities to offer classes related to cannabis, on subjects like growing and processing. These institutions will be able to grow and process cannabis in offering these courses.

Although the language of the bill itself has yet to be published, the framework of SB 350 provides a guide for regulators to implement a program, as well as regulations, that remedies the inequities surrounding the prohibition of cannabis, and, to establish a fair system for the taxation, consumption, and regulation of adult-use cannabis in Pennsylvania.

This story was originally published on Green Market Report.

AUTHORS: Haley Keefer, Darren Kaplan and Garrett Graff – Hoban Law Group

PUBLISHER: CANNABIS LAW REPORT

What Canopy Growth Investors Need to Know About the Houseplant Deal

Steven Lachard

-

March 27, 2019

0

What Canopy Growth Investors Need to Know About the Houseplant Deal

This morning, international cannabis giant Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) welcomed a new Canadian cannabis brand called Houseplant to the company’s existing star-backed product lineup which includes Leafs by Snoop and more.

Founded by British Columbia-born comedian Seth Rogen and his childhood friend and screenwriter Evan Goldberg, Houseplant “has chosen each component of their offering to deliver the highest quality product to Canadians.”

With shares of CGC trading down over 4% in intraday trading following the news, many Canopy investors are left with a few questions unanswered.

How Much is Canopy’s Stake in Houseplant?

Canopy’s announcement notes that “through a minority ownership in the new business venture, Canopy Growth will help Houseplant scale quickly and support Houseplant’s long-term success.” This has left many wondering how large of a stake in Houseplant Canopy owns.

According to a statement from Houseplant, “Canopy acquired 25 per cent of the business, and invested working capital,” but wasn’t willing to dive any deeper into the details.

Are There Any Other Cooks in the Kitchen?

In addition to Canopy, Rogen and Goldberg partnered with their talent reps, United Talent Agency, through its business ventures group.

Doesn’t The Cannabis Act Prohibit Endorsements?

Ever since Canada legalized adult-use cannabis in October 2018, Canadian licensed producers like Canopy are forced to abide by strict laws and guidelines regarding the marketing or promotion of marijuana products.

According to The Canada Press, “The Cannabis Act prohibits the promotion of cannabis, cannabis accessories or any service related to cannabis by means of a testimonial or endorsement or by means of the depiction of a person, character or animal, whether real or fictional.”

The Cannabis Act also makes it so that licensed producers may not “present cannabis or any of its brand elements in a manner that “evokes a positive or negative emotion” about a “way of life such as one that includes glamour, recreation, excitement, vitality, risk or daring.””

Lastly, and obviously, “any promotion that could be seen as appealing to young people is also forbidden.”

Houseplant clarified Rogen and Goldberg’s involvement, making clear that the two are real entrepreneurs and business-owners who have been decision-makers and business developers since day one.

The company said in an emailed statement to The Canada Press:

“Since inception the Houseplant team has maintained a strong focus on abiding by the regulations which is why, not due to a lack of opportunity both pre and post legalization, Seth and Evan have not participated in any cannabis related event or promotion in Canada. They are founders and owners, not spokespeople for the brand and have been very careful not to confuse that.”

What is Canopy’s Role in Houseplant’s Future?

Under the terms of the partnership, “Houseplant will lean on the production and distribution capabilities of Canopy Growth and its licensed subsidiaries to ensure an ample supply of Houseplant flower, Softgel, and pre-rolled formats are rolled out in Canada over the coming months.”

All of the Houseplant strains will be grown at Canopy Growth’s Smiths Falls, Ontario facilities, while Houseplant’s marketing and operational team are based in Toronto.

Seth Rogen Joins The Marijuana Industry Via Canopy Growth

Brendan Bures

-

March 27, 2019

0

Seth Rogen Joins The Marijuana Industry Via Canopy Growth

Seth Rogen is known for making movies in which characters often explore their love of cannabis. It makes sense these movies, ones like Pineapple Express, This Is The End, and Superbad, all serve as touchstones for those who already love cannabis. But now Rogen wants to make it easier for people to learn to love cannabis. Seth Rogen joins the marijuana industry via Canopy Growth.

That’s why Rogen, along with his long-term creative partner Evan Goldberg, are teaming up to create Houseplant, which will be a recreational Canadian marijuana company. “The result of years of experience and dedication,” the company said in a press release, Houseplant is also backed in collaboration with the Ontario-based grower Canopy Growth.

“Houseplant is a passion we’ve brought to life through drive and dedication,” Rogen said in the press release. “Every decision we’ve made for the business reflects the years of education, first-hand experience and respect we have for cannabis.”

The company’s first strain will be called Houseplant Sativa, which will be available for purchase this April in British Columbia, Canada. In addition, the company will release a Houseplant Hybrid and Houseplant Indica strains, as well as soft gels and prerolled joints, later this year.

“We are so proud to be launching in Canada, our home,” Goldberg said. “After spending five years diligently preparing for the launch of this company, we’re excited to be able to share our passion for cannabis with Canadians in this way.”

While Houseplant plans to make marijuana education “the center of its mission,” it’s unclear exactly how they plan to do so. However, it’s another win for Canopy. Last month the company tapped Martha Stewart to launch a line of CBD products for both animals and humans.

Meghan Markle Is ‘A Bit Of A Social Climber,’ Says Piers Morgan; Rob Lowe Jokes That He Made His Sex Tape Too Early

Naughty Gossip

-

March 27, 2019

0

Meghan Markle Is ‘A Bit Of A Social Climber,’ Says Piers Morgan; Rob Lowe Jokes That He Made His Sex Tape Too Early

Meghan Markle is ‘a bit of a social climber,’ says Piers Morgan: ‘Good luck to Harry’

The British broadcaster appeared Thursday on Australia’s “Today” show, where he slammed the Duchess of Sussex and labeled her a “social climber.”

When journalist Deborah Knight asked the 53-year-old if the former American actress “is really fake and a piece of work” as he’s called her before, Morgan immediately quipped, “You know what I’m sorry to have to say I’m afraid I think she is.”

“Although some people really like her and are falling for this act I’m afraid I see a bit of hard-nosed actress,” he explained. “She’s been using people on her way up to what is now, of course, the top, which is marrying into the royal family.”

Morgan alleged he and the former “Suits” star, 37, were friends back in 2016 before she married Britain’s Prince Harry in May 2018 and officially became a member of the royal family.

“I had a couple of pints of real ale and she had dirty martinis,” he claimed. “She said afterward in the cab, ‘I had a great time. Love to see you again.’ It was purely platonic I hasten to add. She went in that cab that night to a party Prince Harry was at and the next night she went on the date with him. I never heard from her again. Ever. I don’t like people that behave like that. It’s kind of rude. It showed me that she, I’m afraid, is probably a bit of a social climber.”

Morgan alleged he “got to know her quite well” over the two-year period, insisting they “would message each other a lot, email a lot.”

But Morgan shared he was unimpressed with the way the 37-year-old treated him after she began dating Harry, 34, immediately disappearing.

“Good luck to Harry,” said Morgan. “I hope he knows what he’s doing. If it all goes wrong don’t come crying to me. Don’t say I didn’t warn you.”

Adam Lambert Goes Instagram Official with New Man

Adam Lambert shared photos of he and his new boyfriend, model Javi Costa Polo, on Instagram. The couple sat together at this year’s Oscars ceremony but this is the first time Lambert has posted a photo (several) of them together.

Lambert wrote “LUV U” in the caption and Costa replied “I love you” back.

One commenter asked, “So @adamlambert you’re finally making it official? You’re with @javicostapolo as a couple?”

And Lambert replied: “honey we have been official for months. IG isn’t the gatekeeper of our truth!”

Rob Lowe jokes that he made his sex tape too early: ‘It would have helped my career’

Rob Lowe has come a long way since a sex tape scandal in the 1980s nearly ruined his then-blossoming acting career. However, looking back now the star says he doesn’t regret the tape as much as he does its timing.

For those unfamiliar, Lowe was the subject of a major scandal in 1988 when he filmed himself having sex with a woman who turned out to be underage the night before promoting Michael Dukakis at the Democratic National Convention. He settled a lawsuit with the girl’s family, was never charged with a crime and maintained that he wasn’t aware she was underage given that they met in a nightclub. However, the rumors and innuendo marred his career at a time when his star should have been on the rise thanks to “St. Elmo’s Fire.”

Speaking on the “WTF Podcast with Marc Maron” recently, the now 55-year-old star opened up about the scandal and joked that it would have helped him later in life.

“The real f— up was that I didn’t wait 20 years later to do it where it would have helped my career,” he said, joking that he could have capitalized on the trends of celebrities like Kim Kardashian and Paris Hilton, who parlayed leaked sex tapes into successful show business careers.

Despite being able to joke about it now, Lowe notes that the backlash was a very negative presence in his life at the time.

“It’s 30 years ago, so it’s hard for me to remember a lot of it. But, my notion of it was all like… happening so fast, and that it was just sort of putting one foot in front of the other.”

“It ends up being the greatest thing that ever happened to me,” he said of his sex tape. “Because what it ends up doing is accelerating my alcohol [addiction] to where I finally get sober. I have been able to have the rest of my life that I’m so blessed with, which is now 20 years of sobriety.”

Sessions Is Gone, Administration Is Still Blocking Marijuana Research

Mike Adams

-

March 27, 2019

0

Sessions Is Gone, Administration Is Still Blocking Marijuana Research

The cannabis community would like to think that former U.S. Attorney General Jeff Sessions was solely responsible for sandbagging medical marijuana research, but it turns out that the Trump Administration, as a whole, really just doesn’t give two flying squirts about developing a functional program that allows scientists to dig deeper into the therapeutic potential of this plant. Even though Session is gone, the administration is still blocking marijuana research.

Although the Drug Enforcement Administration (DEA) announced a few years back that it would license more cannabis growers that just the University of Mississippi to produce research marijuana, the agency still hasn’t made good on its promise. The concept of putting on new pot farmers sort of came to a screeching halt after President Trump appointed Jeff Sessions as the leading law enforcement hammer of the United States. Without so much as a word on the matter, Sessions, who wore his aversion to marijuana on his sleeve, shelved the application process until further notice.

Everyone understood this meant indefinitely.

But Sessions has been out for a while now, and the U.S. Justice Department (DOJ) still hasn’t taken any strides with respect to the approval of more cultivation licenses. There are reportedly 25 applications sitting in a file cabinet somewhere just waiting for the clearance to go to work, but that doesn’t appear likely to happen anytime soon. There are “no updates on this at the moment,” DEA spokesman Rusty Payne told Vox. The agency is “still working through the process with the Department.”

It could be argued (not by us but by somebody) that the Justice Department has just been too wrapped up in other business to make marijuana licensing a priority. There is all of this noise over whether President Trump conspired with the Russians during the 2016 election, not to mention the recent battle over whether he is actually permitted to block his haters from Twitter. So, it is easy to see that the DOJ is far too busy saving the president’s tail to get serious about growing more weed in the U.S.

But it needs to.

Researchers have complained for years that the quality of the University of Mississippi’s pot is one of the main reasons there are all of these unanswered questions regarding the medicinal value of the cannabis plant. They have referred to the product as “green dust,” and even claimed that it doesn’t have the potency needed for a proper analysis.

Opening the scene up to more qualified cannabis growers is the first step in learning more about the cannabis plant. And more accurate research is definitely needed.

There are so many conflicting reports right now over the pros and cons of cannabis that the time has come when the federal government should be clearing the way, by any means necessary, to finds answers. But it is not.

There is hope that Sessions’ replacement, William Barr, might step up and remedy the situation. While he is not necessarily in favor of legalization, he has taken a much more progressive approach to the subject than his predecessor. Even though Session is gone, the administration is still blocking marijuana research and we hope it will change.

But we’re talking about the Trump administration here. If we’ve learned anything over the past couple of years it’s that there will always be something louder to take precedence over real progress.

The Fresh ToastThe most trusted name in cannabis

Fast Food Chain Wants To Personalize Munchie Cravings

The White House Lying About Marijuana And Fentanyl?

How Medical Marijuana Can Help With ADD And ADHD Focus

From hyperactivity to impulses and inattentiveness, ADD and ADHD are most common in children but can persist in adult years.

Tom Brokaw Comes Out As Medical Marijuana User And Advocate

CVS Will Now Sell CBD Oil In 8 States

Pennsylvania Senators Unveil Bill To Foster An Adult-Use Cannabis Program

What Canopy Growth Investors Need to Know About the Houseplant Deal

How Much is Canopy’s Stake in Houseplant?

Are There Any Other Cooks in the Kitchen?

Doesn’t The Cannabis Act Prohibit Endorsements?

What is Canopy’s Role in Houseplant’s Future?

Seth Rogen Joins The Marijuana Industry Via Canopy Growth

Meghan Markle Is ‘A Bit Of A Social Climber,’ Says Piers Morgan; Rob Lowe Jokes That He Made His Sex Tape Too Early

Meghan Markle is ‘a bit of a social climber,’ says Piers Morgan: ‘Good luck to Harry’

Adam Lambert Goes Instagram Official with New Man

Rob Lowe jokes that he made his sex tape too early: ‘It would have helped my career’

Sessions Is Gone, Administration Is Still Blocking Marijuana Research

Don't Miss Your Weekly Dose of The Fresh Toast.